SUZIKI SLING HOT

Sunday, October 31, 2010

SUZIKI SLING HOT








VEHICLE SUMMARY

Name:SlingShot
Type:Commuter


ENGINE SPECIFICATIONS

Displacement:124cc
Engine:Four-stroke, SOHC
Maximum Power:8.5 Bhp @ 7500 rpm
Maximum Torque:10 Nm @ 3500 rpm
Gears:5 Speed
Clutch:Wet Multiplate type
Bore:53.5
Stroke:55.2
No. of Cylinders:1
Cylinder Configuration:NA
Engine Block Material:NA
Chassis Type:NA
Cooling Type:Air Cooling
Carburetor:NA

OTHER SPECIFICATIONS

Weight:127.00 kg
Ground Clearance:160.00 mm
Fuel Tank:12.00 ltrs
Wheelbase:1265.00 mm
Electrical System:NA
Headlamp:12V 35/35W
Battery Type:9.0 KC 10HR
Battery Voltage:12V
Battery Capacity:2.5 Ah
Horn:NA
Wheel Type:Alloys
Wheel Size:2.75x18 - 3.00x-18 mm
Tubeless:
Colors:Yellow, Red, Black, Orange


ACTIVE AND PASSIVE SAFETY

Suspension(Front):Telescopic, Coil spring
Suspension(Rear):Swing-arm, Coil spring
Brakes:Drum
Brakes(Rear):Drum
Stand Alarm:



OMFORT AND CONVENIENCE

Fuel Guage:Analogue
Self Start:
Tacho Meter:Analogue
Trip Meter:Analogue-1
Alloys:
Warranty:NA
Speedometer:Analogue
Passenger Footrest:
Passenger Backrest:
Step-up Seat:
Pass-light:
Low Fuel Indicator:
Low Oil Indicator:
Low Battery Indicator:
High Oil Temp. Indicator:
Choked Air Filter Indicator:


SYMPTOMS ABOUT THE KIDNEY STONES

SYMPTOMS ABOUT THE KIDNEY STONES






Symptoms of kidney stones (aka, renal calculi) vary from person to person, but most people experience severe pain. Kidney stone pain is characterized by its severity.

The excruciating pain is usually centralized in the back or sides and sometimes moves as the stone moves. During an attack, many sufferers experience nausea and vomiting.

They may discover blood in their urine. About eighty percent of stones are small enough to be passed without symptoms and there are some people that have kidney stones but never experience pain.

The other twenty percent of stones make renal calculi one of the most dreaded health conditions.


Kidney stones have been plaguing the human race for a long time. Archaeologists have discovered kidney stones along with human remains in 3,000 year old Egyptian mummies!

It is estimated that three percent of the world's population will suffer from kidney stones in their lifetime. White American males are the most likely to have kidney stones, with a 1 in 8 chance.

MEANS OF KIDNEY

What are Kidney Stones



Kidney stones are the result of crystals that form in your urine and they can be of several different compositions. There are three types of stones that are the most popular.

The most common type of stone is the calcium stone. Seventy to eighty percent of all stone sufferers have calcium stones.

Struvite stones make up about twelve percent of all kidney stones. Struvite stones are made of magnesium ammonium phosphate and are associated with UTI's (urinary tract infections). These stones can be especially damaging to the kidney.

Ten percent of stones are made from uric acid which is related to metabolizing protein. These stones are often pear or diamond in shaped.


What Causes Kidney Stones
Many factors can make a person suspectable to kidney stones. Genetics are two of the biggest culprits. Dehydration makes urine more concentrated and therefore more likely to produce stones.

That is acidic is more likely to form calcium and uric acid stones, whereas alkaline urine will form struvite stones.

Diets that are low in fiber and , and high in protein can promote the formation of kidney stones. Uric acid stones can form when there is too much uric acid in the urine.

This can be the result of severe dieting, excessive drinking, and certain illnesses. Fifteen percent of uric acid stone suffers have high levels of uric acid in their urine.

How Do I Get Tested for Kidney Stones


The easiest test for kidney stones is to retrieve a stone you have passed! If you believe you may be passing a stone for the first time, be sure to look for it in your urine and retrieve it.

Having the stone will allow for your doctor to analyze the composition and offer you the most effective treatment. Other methods such as ultrasound and x-rays can also be used to check for kidney stones. Calcium stones will show up as white on an x-ray.







NEW DISEASE ABOUT VIRUS





New diseases and renewed threats

During the past 20 years, at least 30 new diseases have emerged, for many of which there is no treatment, cure or vaccine, or the possibility of effective prevention or control.


In addition, the uncontrolled and inappropriate use of antibiotics has resulted in increased antimicrobial resistance and is seriously threatening drug control strategies against such common diseases as tuberculosis, malaria, cholera, dysentery and pneumonia.


EMERGING infectious diseases are those whose incidence in humans has increased during the last two decades or which threatens to increase in the near future.


The term also refers to newly-appearing infectious diseases, or diseases that are spreading to new geographical areas - such as cholera in South America and yellow fever in Kenya.

It refers also to diseases that were easily controlled by chemotherapy and antibiotics, but which have developed anti-microbial resistance.

The diseases in question involve all the major modes of transmission - they are spread either from person to person, by insects or animals, or through contaminated water or food.


The most dramatic example of a new disease is AIDS, caused by the human immunodeficiency virus (HIV). The existence of the virus was unknown until 15 years ago, but it has since then infected an estimated 24 million adults worldwide, and that number could grow to a cumulative total of 40 million by the year 2000.

The origins of HIV are unknown, but it is related to viruses which cause AIDS-like illness in monkeys. Microorganisms constantly undergo changes that enable them to cope with an increasingly hostile environment in their hosts.




For example, HIV exploits weaknesses in the host's defences by damaging the human immune system, thereby allowing other 'opportunistic' infections to take advantage.

A new breed of deadly haemorrhagic fevers, of which Ebola is the most notorious, has struck in Africa, Asia, the United States and Latin America.


Ebola appeared for the first time in Zaire and Sudan in 1976; it has since struck in Cote d'Ivoire in 1994 and 1995, Liberia in 1995 and again in Zaire in 1995, where it was fatal in 77% of cases.


The United States has seen the emergence of hantavirus pulmonary syndrome, characterised by respiratory failure and a case fatality rate of over 50%.

Since it was first recognised in 1993, this type of hantavirus infection has been detected in more than 20 states in that country, and has also surfaced in Argentina and Brazil.


This hantavirus is carried by rodents, particularly deer mice, and other hantaviruses have been recognised for many years in Asia, where they cause haemorrhagic fever with renal involvement in humans.

Epidemics of food-borne and water-borne diseases due to new organisms such as cryptosporidium or new strains of bacteria such as Escherichia coli have hit industrialised and developing countries alike.


The O157:H7 strain of E.coli was first reported in 1982 and has since then been implicated in many serious outbreaks of diarrhoeal illness, sometimes leading to kidney failure. The strain has been linked to undercooked hamburger beef and unpasteurised milk.

A completely new strain of cholera, 0139, appeared in south-eastern India in 1992 and has since spread north and west to other areas of India, into western China, Thailand and other parts of South-East Asia.

The threat of a new global influenza pandemic is increasing. Major shifts in the make-up of influenza viruses occur every 20 years or so, triggering large epidemics in many parts of the world, and causing many thousands of deaths. The next such shift is expected to take place very soon.



Epidemic strains of influenza viruses originate from China. The influenza virus is carried by ducks, chickens and pigs raised in close proximity to one another on farms. The exchange of genetic material between these viruses produces new strains, leading to epidemics of human influenza, each epidemic being due to a different strain.

New strains such as those of cholera and influenza do not follow the usual pattern of being more common in younger people. They affect all age groups, since older people have not acquired immunity to them from previous infection.

The emergence of drug-resistant strains of microorganisms or parasites is promoted by treatments that do not result in cure. The increasing use of antimicrobials worldwide, often in subtherapeutic doses and sometimes in counterfeit form, guarantees that this problem will increase in the foreseeable future....

Changes in lifestyle, behaviour (including injecting and non-injecting drug use) and cultural or social values are behind the emergence of some infectious diseases such as syphilis.

Increases in the number of sexual partners have been the main factor in the spread of HIV infection and other sexually transmitted diseases.



Travel, including tourism, also plays a role. The spread of syphilis in the 18th and 19th centuries was related to the movement of armies.

, the introduction of HIV in many parts of the world is due to greatly increased human mobility. Studies show that whereas only a few generations ago most people in their lifetime travelled no further than 40 kilometres from their birthplace, many today go up to 1,000 times further, travelling the whole world.\


The practices of modern medicine also contribute. The spread of viral hepatitis is related in part to techniques such as kidney dialysis and multiple blood transfusions, as well as to other forms of transmission.


KIDNEY

Relaxation in immunisation practices can quickly result in the resurgence of diseases, as, for example, the recent spread of diphtheria in the Russian Federation and other former republics of the USSR.

New animal diseases pose potential food-borne risks to human health that are sometimes difficult to evaluate or predict. An example that has caused much public concern in Europe is bovine spongiform encephalopathy ('mad cow disease').

Fears have grown that the infectious agent responsible may be passed through the food chain to cause a variant of the incurable Creutzfeldt-Jakob disease in humans, in which the brain is attacked. The British beef market has been seriously affected and stringent public health safeguards have been introduced.

The reasons for outbreaks of new diseases, or sharp increases in those once believed to be under control, are complex and still not fully understood. The fact is however that national health has become an international challenge. An outbreak anywhere must now be seen as a threat to virtually all countries, especially those that serve as major hubs of international travel.

Despite the emergence of new diseases in the last 20 years, there is still a lack of national and international political will and resources to develop and support the systems that are necessary to detect them and stop their spread.


Without doubt diseases as yet unknown, but with the potential to be the AIDS of tomorrow, lurk in the shadows.

Antimicrobial resistance

Resistance by disease-causing organisms to antimicrobial drugs and other agents is a major public health problem worldwide.

It is making a growing number of infections virtually untreatable, both in hospitals (as discussed in the later section on hospital infections) and in the general community.

It is having a deadly impact on the control of diseases such as tuberculosis, malaria, cholera, dysentery and pneumonia.

Antimicrobial resistance is not a new problem, but it has worsened dramatically in the last decade. During that time, the pace of development of new antimicrobials has slowed down while the prevalence of resistance has grown at an alarming rate.

The increase in the number of drug-resistant bacteria is no longer matched by a parallel expansion in the arsenal of agents used to treat infections.

Human Breast Cancer Cells Linked to Development of an Aggressive

Friday, October 29, 2010

Human Breast Cancer Cells Linked to Development of an Aggressive, But Less Common Form of Breast Cancer





Scientists have identified a group of surface markers on cells linked to an aggressive type of breast cancer called estrogen receptor-negative cancer.

In this preliminary study, estrogen-negative breast cancer developed when three markers, CD44+, CD49fhi, and CD133hi were present simultaneously on the surface of human cells taken from breast cancer patients and transplanted into a mouse; this is called a xenograft model.

The scientists named these human cells with tumor-forming ability in mice, xenograft-initiating cells, or XIC.

The research, conducted by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, appeared online May 18, 2010, and in print June 1, 2010, in Cancer Research.





Tumor cells were labeled with a fluorescent marker and then introduced into the mouse’s circulation by tail vein injection. Subsequently, the lungs were excised, filled with agarose—a type of complex carbohydrate—to provide structural support, sliced, and placed in culture.


This allowed the researchers to follow the growth of the tumor cells over time, and to view growth from single cells to proliferating cell colonies. In each case the cells that were highly metastatic in mice were also highly metastatic in the PuMA. The same was true for low metastatic cells.




With this validation in place, the team showed that the assay also provided an opportunity to evaluate new cancer drugs for their specific effects on metastatic progression.

This is important because most cancer drugs in development screen for anti-cancer activity in primary tumor growth and not in metastasis.


The scientists also demonstrated, for the first time, that the common markers CD44+, CD24- on the surface of stem cells were not necessarily or exclusively associated with growth in tumors of estrogen receptor-negative breast cancer.


The identification of XIC may encourage investigators to re-evaluate the merits of therapeutically targeting CD44+, CD24-.



http://www.cancer.gov/images/documents/7c6a7bd5-33cc-4265-a5ab-5442f36ca2b2/SMcroppedXIC.jpg

The identification of specific markers on cells that are associated with estrogen receptor-negative breast cancer is important because this type of breast cancer is more difficult to treat than estrogen receptor-positive breast cancer.


Estrogen receptor-positive breast cancers may be treated with medications such as tamoxifen, which interfere with the activity of estrogen. But no targeted therapies are yet available for patients with estrogen receptor-negative breast tumors.


These cancers are currently treated with chemotherapy drugs that are toxic to many cells, not just cancer cells, and which can be hard for patients to tolerate.


Surface markers, usually proteins, are visualized on many cell types using antibodies or other detection methods.


To identify surface markers of estrogen receptor-negative breast cancer stem-like cells, the investigators tested different populations of human breast cancer cells for their ability to form tumors when injected into the fat pads of the mammary glands of mice with compromised immune systems.


The various tumor cell populations were prepared by a technique called flow cytometry, in which distinct antibodies bind to specific cell surface markers, resulting in separate subpopulations of cells.





Scientists Develop Model that Advances Understanding of the Process of Cancer Metastasis

Scientists Develop Model that Advances Understanding of the Process of Cancer Metastasis

Tumor cells were delivered to mice by tail-vein injection.


Metastasis of a tumor from its primary site to other parts of the body continues to be the main reason why people die from cancer.

The group theorized that introducing tumor cells into animals just prior to performing a lung culture might allow them to study the metastatic progression as it was happening. With this aim in mind, they developed an ex vivo (PuMA) in which cancer cells marked with a fluorescent molecule can be viewed during metastatic progression—from a single tumor cell to a secondary site in the lung.






The scientists acknowledge that there are other approaches to studying metastasis in animals, in real-time, but explain that those approaches require microscopic tools that are not widely available and not amenable to the study of the lung.

The PuMA allows the serial assessment of metastatic progression without such instruments and provides a new window into the steps involved in metastatic progression






n this experiment, the scientists compared a series of high and low-potential metastatic cells both in mice and in the PuMA. Malignant tumors are composed of cells with different characteristics and only certain cells have metastatic potential; the establishment of cell lines with high or low metastatic potential is necessary to investigate the molecular mechanisms of the metastatic process.



Immunotherapy Boosts Pediatric Cancer Survival

Boosts Pediatric Cancer Survival







A microscopic slice of a neuroblastoma cell, stained blue, and showing a rosette formation typical of the cancer
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years.

The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study in the Sept. 30, 2010, New England Journal of Medicine.




Neuroblastoma is a cancer of the peripheral nervous system (found outside of the brain and spinal cord), and is responsible for 12 percent of all deaths due to cancer in children under 15 years of age.

It is the most common non-brain solid tumor in children. Nearly 50 percent of patients with neuroblastoma have a high-risk form of the disease and have poor long-term survival despite very intensive treatment.

The previously established standard treatment for neuroblastoma uses high doses of chemotherapy to destroy as many cancer cells as possible. But this form of chemotherapy (myleoablative therapy) also destroys some normal blood-forming cells, so it is followed by giving back previously collected blood-forming cells to restore immune system function and blood cell formation

The phase III trial results establish ch14.18 immunotherapy as a new standard treatment for children with high-risk neuroblastoma,” said Alice Yu, M.D., Ph.D., University of California, San Diego and study chair of the clinical trial.


Because there was no pharmaceutical company to make ch14.18 when the phase III trial started, NCI manufactured the agent and provided it to COG for the clinical trial. NCI continues to manufacture ch14.18 and to make it available to children with high-risk neuroblastoma through ongoing Children’s Oncology Group clinical trials.